Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Erlowel
Erlowel (Erlotinib 150 mg) is an advanced targeted cancer therapy designed to inhibit tumor growth by blocking the EGFR pathway. It is effective in treating non-small cell lung cancer (NSCLC) and pancreatic cancer.
Uses of Erlowel
Non-small cell lung cancer (NSCLC): Used as first-line or maintenance therapy in EGFR mutation-positive cases.
Pancreatic cancer: Combined with chemotherapy to slow disease progression.
Benefits of Erlowel
Targeted action: Specifically inhibits EGFR, reducing cancer cell proliferation.
Oral therapy: Convenient, non-invasive treatment option.
Proven efficacy: Helps improve progression-free survival in NSCLC and pancreatic cancer.
Well-studied treatment: Used globally in oncology care.
Mechanism of Action of Erlowel
Erlotinib is a tyrosine kinase inhibitor (TKI) that selectively blocks the epidermal growth factor receptor (EGFR). By preventing EGFR activation, it disrupts cancer cell signaling pathways, leading to reduced tumor growth and apoptosis (cell death).